Inoviq Ltd

IIQ.ASX

Health Care

Developing exosome diagnostics and therapeutics for cancer

Market Data

Price

$0.325

+0.0%
Market Cap

$45.0M

P/E Ratio

-100000.0x

EPS

$-0.061

Div. Yield

0.00%

52-Week Change

-0.4%

Latest Earnings

Appendix 4D and FY26 Half Year Financial Report

18 February 2026

Revenue
$0.23
+10.7% YoY
NPAT
-$3.96
-8.3% YoY
EPS
$-0.03

INOVIQ reported an 11% increase in product revenue to $229,584 but net loss widened 8% to $3.96M due to higher R&D spending. The company raised $10.2M in capital and ended with $13.8M cash, positioning it to advance its exosome diagnostic and therapeutic pipeline programs. Key points: Successful $10.2M capital raise including $5M cornerstone investment from Tian An Medicare; EXO-OC ovarian cancer test demonstrates 100% sensitivity for early-stage cancer with >99.6% specificity; CAR-exosome therapy shows 61.5% reduction in tumor burden in preclinical studies

Recent Announcements

18 Feb 2026 Actual Results Neutral

Appendix 4D and FY26 Half Year Financial Report

INOVIQ reported an 11% increase in product revenue to $229,584 but net loss widened 8% to $3.96M due to higher R&D spending. The company raised $10.2M in capital and ended with $13.8M cash, positioning it to advance its exosome diagnostic and therapeutic pipeline programs. Key points: Successful $10.2M capital raise including $5M cornerstone investment from Tian An Medicare; EXO-OC ovarian cancer test demonstrates 100% sensitivity for early-stage cancer with >99.6% specificity; CAR-exosome therapy shows 61.5% reduction in tumor burden in preclinical studies

Get real-time alerts for IIQ

Receive AI-powered earnings summaries and instant notifications when Inoviq Ltd releases results.

Register Free